This article provides a comprehensive overview of the performance validation of circulating tumor DNA (ctDNA) assays, a critical component for their reliable integration into oncology research and drug development.
Accurate quantification of next-generation sequencing (NGS) libraries is a critical, yet often overlooked, step that directly impacts sequencing success, cost-efficiency, and data quality.
This article provides a systematic examination of the inter-platform reproducibility of droplet digital PCR (ddPCR), a critical factor for its application in biomedical research and drug development.
This article provides a comprehensive comparison of digital PCR (dPCR) and quantitative PCR (qPCR) for the analysis of circulating tumor DNA (ctDNA), a critical biomarker in liquid biopsy.
This article explores the established and emerging evidence for the concordance between droplet digital PCR (ddPCR) and tissue biopsy in detecting tumor-derived genetic alterations.
This article provides a detailed comparison of droplet digital PCR (ddPCR) and Next-Generation Sequencing (NGS) for liquid biopsy applications, focusing on cost, performance, and suitability for research and drug development.
This article provides a detailed examination of sample storage conditions critical for maintaining circulating tumor DNA (ctDNA) stability in liquid biopsy applications.
This article provides a comparative analysis of digital PCR (dPCR) and Next-Generation Sequencing (NGS) for researchers and drug development professionals.
This article provides a comprehensive comparison of droplet digital PCR (ddPCR) and next-generation sequencing (NGS) for circulating tumor DNA (ctDNA) analysis, crucial for precision oncology.
This article provides a comprehensive guide for researchers and drug development professionals on establishing robust analytical thresholds for rare mutation detection.